Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 478 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+ - NCT06961526Recruiting
Preventing varices bleeding in liver cancer patients on immunotherapy
This trial tests if preventing esophageal varices (swollen veins in the food pipe) can reduce bleeding risk in people with advanced liver cancer who are receiving a combination of two drugs (atezolizumab and bevacizumab). It may help those with good liver function and no high-risk varices at the start.
Tanta, GharbyeaAges 18 years+ - NCT06961617RecruitingPhase 1
Immune cell therapy for advanced hepatitis B-related liver cancer
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
BeijingAges 18–70 - NCT07132515RecruitingPhase 4
Blood thinners for cirrhosis with portal vein clot
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
Al Mansurah, Dakahlia GovernorateAges 18–70 - NCT07123545RecruitingPhase 1/Phase 2
Personalized T-cell therapy for advanced liver cancer
This trial tests a personalized treatment using your own immune cells (T-cells) trained to attack specific markers on your liver cancer. It is for people with advanced liver cancer that has worsened after at least two prior treatments and who have tumor tissue available for genetic testing.
Hangzhou, ZhejiangAges 18–75 - NCT07118202Recruiting
TheraBionic device for advanced liver cancer
This trial tests a device called TheraBionic P1 for people with advanced liver cancer that has not responded to other treatments. It may be an option if you have tried at least two prior therapies or cannot take standard treatments.
Bay City, MichiganAges 22 years+ - NCT07116486RecruitingPhase 1
Using a new PET scan to guide liver cancer treatment
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
Houston, TexasAges 18 years+ - NCT07100392RecruitingPhase 2
A new drug combo for advanced liver cancer after first treatment fails
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06911255RecruitingPhase 1/Phase 2
Testing two immunotherapy drugs with chemoembolization for liver cancer
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
SeoulAges 19 years+ - NCT07088081Enrolling by invitation
Immunotherapy drugs for advanced liver cancer
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Cairo, AbbasyaAges 18 years+ - NCT07077356RecruitingPhase 1
mRNA vaccine for liver cancer patients awaiting transplant
This trial tests an mRNA vaccine for people with liver cancer who are waiting for a liver transplant. The vaccine is given to help control the cancer while they wait.
ChengduAges 18 years+ - NCT06978933RecruitingPhase 2
Testing two new drugs for FGF19-positive liver cancer
This trial tests two new targeted drugs (ABSK-011 and ABSK043) for people with advanced liver cancer whose tumors have high levels of the FGF19 protein and who have already tried at least one other treatment.
ShanghaiAges 18 years+ - NCT07070076Recruiting
Y-90 therapy vs chemo infusion for liver cancer
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
Guangzhou, GuangdongAges 18–75 - NCT07075120RecruitingPhase 1
Immunotherapy and radiation for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
Honolulu, HawaiiAges 18 years+ - NCT06741020RecruitingPhase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hangzhou, ZhejiangAges 18–75 - NCT07052253RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests two experimental drugs (AK104 and AK112) combined with an oral tablet (TT-00420) for people with advanced hepatocellular carcinoma (a type of liver cancer) who have not had previous systemic treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Wuhan, ChinaAges 18–75 - NCT07047586RecruitingPhase 2
Lenvatinib plus Tislelizumab vs Lenvatinib alone for liver cancer
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07039201Recruiting
A cell therapy for liver cancer that has progressed on other treatments
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hangzhou, ZhejiangAges 18–75 - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT07036874Recruiting
Predicting outcomes in liver cancer with non-invasive tests
This study uses non-invasive tests, like scans or blood tests, to predict how well people with liver cancer (hepatocellular carcinoma, or HCC) will do after curative treatment. It may help doctors better understand your condition without needing invasive procedures.
Hong KongAges 18 years+ - NCT07027436RecruitingPhase 3
Immunotherapy plus radiation before liver cancer surgery
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
Hamilton, OntarioAges 18 years+ - NCT06995105RecruitingPhase 1/Phase 2
Personalized mRNA Vaccine for Advanced Liver Cancer
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07019844Recruiting
PSMA PET scan for liver cancer staging
This trial tests if a special PET scan (PSMA PET) can better stage liver cancer that has not been treated yet and is at a moderate to advanced stage (BCLC B or C). It may help guide treatment decisions.
West Los Angeles, CaliforniaAges 18 years+ - NCT07018518RecruitingPhase 1
Pin and immunotherapy combo for advanced liver cancer
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 478 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.